We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+56.2%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$178M
AUM Growth
+$28.4M
Cap. Flow
-$14.1M
Cap. Flow %
-7.93%
Top 10 Hldgs %
56.23%
Holding
58
New
12
Increased
14
Reduced
9
Closed
19

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.29M
2
TRML
Tourmaline Bio
TRML
+$4.64M
3
OCUL icon
Ocular Therapeutix
OCUL
+$3.87M
4
RVMD icon
Revolution Medicines
RVMD
+$3.84M
5
MRSN
Mersana Therapeutics
MRSN
+$3.65M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$8.54M
2
VTYX
Ventyx Biosciences
VTYX
+$7.13M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$4.31M
4
ALKS icon
Alkermes
ALKS
+$3.54M
5
REPL icon
Replimune Group
REPL
+$2.57M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
26
Verastem
VSTM
$519M
$1.89M 1.06%
232,249
+2,249
+1% +$16.2K
APLT
27
DELISTED
Applied Therapeutics
APLT
$1.76M 0.99%
+525,100
New +$1.31M
ELVN icon
28
Enliven Therapeutics
ELVN
$4.31B
$1.71M 0.97%
123,876
+20,276
+20% +$248K
FDMT icon
29
4D Molecular Therapeutics
FDMT
$552M
$1.51M 0.85%
+74,500
New +$980K
CYPH
30
Cypherpunk Technologies Inc
CYPH
$71.7M
$1.47M 0.83%
354,166
– –
CLRB icon
31
Cellectar Biosciences
CLRB
$20.1M
$1.32M 0.74%
15,917
+11,874
+294% +$885K
INSM icon
32
Insmed
INSM
$28.7B
$914K 0.51%
+29,500
New +$765K
ARGX icon
33
argenx
ARGX
$54.8B
$913K 0.51%
+2,400
New +$1.12M
VRNA
34
DELISTED
Verona Pharma
VRNA
$378K 0.21%
+19,000
New +$281K
SWTX
35
DELISTED
SpringWorks Therapeutics
SWTX
$365K 0.21%
+10,000
New +$261K
CNTA
36
DELISTED
Centessa Pharmaceuticals
CNTA
$304K 0.17%
38,138
-285,211
-88% -$1.91M
TYRA icon
37
Tyra Biosciences
TYRA
$1.61B
$123K 0.07%
+8,867
New +$115K
AVXL icon
38
PUT
Anavex Life Sciences
AVXL
$304M
$22.5K 0.01%
+1,000
New +$6.88K
NUVB.WS
39
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$5.45K ﹤0.01%
90,832
– –
ACRS icon
40
Aclaris Therapeutics
ACRS
$851M
– –
-121,692
Closed -$834K
ALKS icon
41
Alkermes
ALKS
$8.11B
– –
-126,500
Closed -$3.54M
BCLI
42
PUT
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
– –
-167
Closed -$825K
BMEA icon
43
Biomea Fusion
BMEA
$90.4M
– –
-39,935
Closed -$550K
ETNB
44
CALL
DELISTED
89bio
ETNB
– –
-1,000
Closed -$1.52M
ETNB
45
DELISTED
89bio
ETNB
– –
-32,800
Closed -$506K
CBIO
46
Crescent Biopharma
CBIO
$610M
– –
-275
Closed -$41.3K
GPCR icon
47
Structure Therapeutics
GPCR
$3.74B
– –
-5,000
Closed -$252K
IMA
48
ImageneBio Inc
IMA
$64M
– –
-45,918
Closed -$2.39M
IONS icon
49
Ionis Pharmaceuticals
IONS
$9.06B
– –
-11,300
Closed -$513K
KRON
50
DELISTED
Kronos Bio
KRON
– –
-718,739
Closed -$934K
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Acuta Capital Partners held 58 positions worth $178M, up 19% from $149M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Acuta Capital Partners withdrew a net $14.1M in Q4 2023, closing 19 positions and reducing 9 holdings. Its most notable exit was Ventyx Biosciences, an estimated $7.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Tourmaline Bio worth $6.07M.

  • Acuta Capital Partners's largest Q4 2023 buy was Tourmaline Bio: 231,882 shares worth $6.07M.
  • Acuta Capital Partners added most to Sarepta Therapeutics in Q4 2023, an estimated $5.29M increase.
  • Acuta Capital Partners's biggest Q4 2023 reduction was Apellis Pharmaceuticals, cutting an estimated $8.54M.
  • Acuta Capital Partners fully exited Ventyx Biosciences in Q4 2023, selling an estimated $7.13M.
  • Acuta Capital Partners's ten largest holdings make up 56% of its $178M portfolio in Q4 2023.
  • Acuta Capital Partners opened 12 new positions and closed 19 in Q4 2023.
  • Acuta Capital Partners's portfolio value rose 19% quarter-over-quarter to $178M.

Based on Acuta Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.